These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11373779)

  • 1. [Chronic hepatitis C and HIV. Current therapeutic options].
    Mauss S
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():46-9. PubMed ID: 11373779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in the treatment of hepatitis B and C co-infection in HIV patients].
    Mauss S
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():27-9. PubMed ID: 15373041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic hepatitis C in HIV-infected patients. Unfavorable interaction of HIV and HCV infection].
    Mauss S
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():60-2. PubMed ID: 10863316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In HIV-HCV co-infection check for drug interactions].
    Neumaier J
    MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259910
    [No Abstract]   [Full Text] [Related]  

  • 5. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
    Bräu N
    J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Groundbreaking new data for HIV and hepatitis B and C. What will change in 2010?].
    Jablonowski H; Mauss S
    MMW Fortschr Med; 2010 Apr; 152(17):26. PubMed ID: 20509255
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 9. [Eliminating the gray zone. What can be done in normal ALT values?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():75. PubMed ID: 15373059
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
    Peters L; Lindhardt BØ
    Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
    Zeuzem S
    MMW Fortschr Med; 2002 Feb; 144(8):30-4. PubMed ID: 11910820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV & hepatitis C: treatment.
    WORLD; 2002 May; (133):4-5. PubMed ID: 12064298
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained viral response after only 6 weeks of peginterferon and ribavirin treatment for acute hepatitis C in a HIV-1-infected patient.
    van den Berk GE; Arends JE
    AIDS; 2011 Jul; 25(12):1553-4. PubMed ID: 21747237
    [No Abstract]   [Full Text] [Related]  

  • 16. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV/HCV coinfection. A good chance of recovery also for dually infected patients].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():7. PubMed ID: 25026843
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dual infection with HIV and HCV. Focus on antiviral therapy].
    MMW Fortschr Med; 2001 Oct; 143(40):54. PubMed ID: 11692848
    [No Abstract]   [Full Text] [Related]  

  • 20. [Increasing chances. Effective HCV therapy lowers mortality of HIV infection].
    MMW Fortschr Med; 2003 Jun; 145(26):53. PubMed ID: 12916340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.